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Sregarding EDD (p¼0.6) and EF (p¼0.2), but Mitraclip patients had higher sPAP
(5216 vs 4215 mmHg,p¼0.02) and tricuspid regurgitation>2 (25% vs 0%,
p¼0.001). MitraClip was successful in all but 1 patient. Postoperative complications
for MitraClip and surgery were respectively: low cardiac output syndrome 8.3% vs
36.4% (p¼0.02), acute kidney disease 16.7% vs 45.4% (p¼0.03), transfusions 8.3%
vs 40.9% (p¼0.009). Median length of stay was 4 vs 8 days (p¼0.0003) and home-
discharge was 91.3% vs 0% (p¼0.0001) respectively. One death occurred in Mitra-
Clip group (p¼0.3). Acute residual MR>2 was 12.5% vs 0% (p¼0.0001) for
MitraClip and surgery. Median follow-up was 1.1(0.6-2) vs 2.8(1.4-4) years for
MitraClip and surgery (p¼0.0005). Compared to baseline NYHA>2 decreased to
13.6% in MitraClip (p¼0.0002) and to 5.3% in surgical (p¼0.01) patients, becoming
similar among the groups (p¼0.3). No difference between MitraClip and surgery was
observed in QoL (all p>0.05). EDD was similar (p¼0.4), but sPAP remained higher
in MitraClip patients (4214 vs 316 mmHg, p¼0.01). Actuarial 1.5 years freedom
from cardiac death for MitraClip and surgery was 91.6% vs 100% (p¼0.2), whereas
freedom from MR>2 was 89% vs 100% respectively (p¼0.01).
Conclusions: Although surgery more effectively reduced MR, superior acute and
short-term clinical beneﬁts were achieved after MitraClip, despite patients older age
and heavier comorbidities burden.
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Background: MVIV has been performed in more than 130 patients worldwide, and
the recourse to this procedure is expected to rise consistently due to the increasing
use of bioprostheses and to the risks related to redo mitral valve replacement.
However, there is some concern that the excellent early hemodynamic results of
MVIV could be nulliﬁed by the development of signiﬁcant transvalvular gradients at
follow-up. We report our experience with MVIV, with particular emphasis on the
follow-up
Methods: From 2010 10 patients underwent MVIV with the Edwards Sapien valve
(THV) at our institution. The mean age was 75.7 years (range 43-87) and the STS
score was 8.4 (3.9-21.9). All patients were heavily symptomatic. The mechanism of
bioprosthesis failure was stenosis (2 patients) regurgitation (1) or mixed (7). The mean
transprosthetic gradient was 12.53.6 mmHg. All the procedures were transapical.
Balloon predilatation was never used
Results: In the ﬁrst patient the transcatheter valve was inﬂated at the level of the
prosthesis sewing ring, it splayed the prosthesis struts and embolized in the ventricle.
The procedure was converted to open surgery and ended with a well-functioning
THV, but the patient died two days later for multi-organ failure. There were no other
in-hospidal deaths. Two patients died during the follow-up, for pneumonia and
endocarditis at 1 and 8 months postoperatively. The mean gradient at discharge fell
signiﬁcantly to 5.21.2 and only 1 patient had moderate intervalvular regurgitation.
At follow-up (median 420 days), all patients were alive and well in NYHA class2.
The mean transprosthetic gradient was 72.7 and 2 patients had a gradient >10
mmHg. In both these patients, the THV had been signiﬁcantly oversized compared to
the surgical bioprosthesis (26 mm Sapien in 25 mm Carpentier and 29 mm Sapien in
29 mm Mosaic)
Conclusions: MVIV is a safe alternative in high risk patients with malfunctioning
mitral prostheses, and allows excellent haemodynamic and clinical results. In our
series, the appearance of a signiﬁcant transvalvular gradient at follow-up was not
associated to echocardiographic signs of structural deterioration, and was possibly
related to the degree of oversizing of the THV
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Background: In the MitraClip procedure, one or more clips are implanted to
reduce mitral regurgitation (MR). Cross-sectional assessment of MR size can be
assessed on three-dimensional transesophageal echocardiography (3D TEE),
however its role in the MitraClip procedure has not been determined. This study
will explore the value of the cross-sectional assessment of MR jet in predicting the
number of clips.
Methods: 3D TEE assessment with color Doppler was performed in 24 patients (age
7311 years; 67% men; 63% functional MR) who underwent successful MitraClip
procedure (reduction of MR to 2+). Manual tracing of MR jet in a cross-sectionalB214 JACC Vol 62/18/Suppl B j October 27–Novemberplane through the level of the valve was obtained (Figure). The curved length and area
of MR jet was compared between patients who received 1 clip (n¼9) and 2 clips
(n¼15).
Results: Patients who received 2 clips had signiﬁcantly larger curved length and area
of MR jet compared to patients who received 1 clip (1.340.5 cm vs. 2.130.5 cm,
p<0.05 and 0.580.4 cm2 vs. 1.060.4 cm2, p<0.05, respectively). In receiver-
operating characteristic analysis, the curved length and area of MR jet had a high
discriminatory value for 2nd clip implantation: This was with the area under the curve
of 0.92 (95% CI, 0.76-1.00; p<0.05) and 0.87 (95% CI, 0.69-1.00; p<0.05),
respectively. A cutoff value of the curved length and area of MR jet was 1.51 cm
(sensitivity¼100% and speciﬁcity¼89%) and 0.59 cm2 (sensitivity¼94% and spe-
ciﬁcity¼78%), respectively.
Conclusions: The cross-sectional assessment of MR jet using 3D TEE is helpful in
determining the number of MitraClip devices.TCT-703
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Background: The ANZ MitraClip Registry is a prospective, fully audited, single arm
study of patients with severe symptomatic mitral regurgitation (MR) treated by
MitraClip implantation. Six month clinical and echocardiographic outcomes are
described.
Methods: The Registry is currently enrolling patients treated at 3 sites in Australia
with plans to include up to 10 sites. Baseline demographics, echo parameters and
functional data were collected at baseline, pre-discharge, 30days, 6 months and 12
months.
Results: To date, 45 patients at high risk for mitral valve surgery have been included
in the Registry. The age was 759yrs (52%>75yrs old), 72% were male, and 72%
had a history of prior cardiac surgery. The majority (76%) had functional MR, 42%
had LVEF <40%. The STS Mortality risk score was 15.813.1%. The procedure time
was 13343mins, ﬂuoroscopy time was 4238mins, and post-procedure length of
stay was 4.04.6days. All patients were discharged home. One clip was implanted in
27%, 2 clips in 62% and 3 clips in 11%. At 30days, there were no deaths, strokes or
myocardial infarctions, and no need for mitral surgery. Major bleeding occurred in 8
patients (18%). At six months, the mortality was 0%. MR severity was moderate to
severe or severe (3-4+) in 24.1% (vs 97.7% at baseline), NYHA class III or IV was
recorded in 16.6% (vs 66.6% at baseline), and 6 minute walk distance had increased
from 265132m to 324170m (p<0.05). When compared with baseline values, the
LV regurgitant volume fell from 60.842.6mls to 30.314.4mls, LVEDV fell from
163.073.1 to 153.391.1mls, and the LVESV fell from 98.969.2 to
95.082.1mls. The LVEF was 45.616.9 at baseline and 45.617.7% at 6mths. The
MLWHF quality of life score was 49.323.2 at baseline and 27.622.8 (p<0.0001)
at six months.
Conclusions: In this prospective study, the majority of patients have been elderly with
multiple co-morbidities and a predominance of functional MR. Although early in each
centre's experience, implant success rates are high, complications are low, and at 6
months, signiﬁcant improvements have been achieved in MR severity, LV mechanics,
functional class and quality of life.1, 2013 j TCT Abstracts/POSTER/Mitral Valve Disease and Treatment
